Smith DC - Search Results

1

Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.

Panella TJ, Smith DC, Schold SC, Rogers MP, Winer EP, Fine RL, Crawford J, Herndon JE 2nd, Trump DL. Panella TJ, et al. Among authors: smith dc. Cancer Res. 1992 May 1;52(9):2456-9. Cancer Res. 1992. PMID: 1533174 Clinical Trial.

2

Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature.

Smith DC, Tucker JA, Trump DL. Smith DC, et al. J Clin Oncol. 1992 Mar;10(3):499-505. doi: 10.1200/JCO.1992.10.3.499. J Clin Oncol. 1992. PMID: 1311029 Review.

3

High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.

Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL. Trump DL, et al. Among authors: smith dc. J Natl Cancer Inst. 1992 Dec 2;84(23):1811-6. doi: 10.1093/jnci/84.23.1811. J Natl Cancer Inst. 1992. PMID: 1359155 Clinical Trial.

4

Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.

Smith DC, Vick NA, Trump DL, Friedman HS, Friedman AH, Purvis J, Gauspari A, Schold SC Jr. Smith DC, et al. Cancer Chemother Pharmacol. 1992;30(4):272-6. doi: 10.1007/BF00686294. Cancer Chemother Pharmacol. 1992. PMID: 1643694 Clinical Trial.

5

Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.

Smith DC, Jodrell DI, Egorin MJ, Ambinder RM, Zuhowski EG, Kreis W, Ellis PG, Trump DL. Smith DC, et al. Cancer Chemother Pharmacol. 1993;31(5):363-8. doi: 10.1007/BF00686149. Cancer Chemother Pharmacol. 1993. PMID: 7679331 Clinical Trial.

6

A phase I trial of high-dose oral tamoxifen and CHOPE.

Smith DC, Trump DL. Smith DC, et al. Cancer Chemother Pharmacol. 1995;36(1):65-8. doi: 10.1007/BF00685734. Cancer Chemother Pharmacol. 1995. PMID: 7720178 Clinical Trial.

7

Adjuvant chemotherapy for bladder cancer. Standard of care or unproven therapy?

Bahnson RR, Smith D, Trump D. Bahnson RR, et al. Surg Oncol Clin N Am. 1995 Apr;4(2):287. Surg Oncol Clin N Am. 1995. PMID: 7796287 Review.

8

Population pharmacokinetics of hydroxyurea in cancer patients.

Tracewell WG, Trump DL, Vaughan WP, Smith DC, Gwilt PR. Tracewell WG, et al. Among authors: smith dc. Cancer Chemother Pharmacol. 1995;35(5):417-22. doi: 10.1007/s002800050256. Cancer Chemother Pharmacol. 1995. PMID: 7850924 Clinical Trial.

9

A phase I trial of high-dose continuous-infusion hydroxyurea.

Smith DC, Vaughan WP, Gwilt PR, Trump DL. Smith DC, et al. Cancer Chemother Pharmacol. 1993;33(2):139-43. doi: 10.1007/BF00685331. Cancer Chemother Pharmacol. 1993. PMID: 8261572 Clinical Trial.

10

Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.

Petros WP, Chaney SG, Smith DC, Fangmeier J, Sakata M, Brown TD, Trump DL. Petros WP, et al. Among authors: smith dc. Cancer Chemother Pharmacol. 1994;33(4):347-54. doi: 10.1007/BF00685911. Cancer Chemother Pharmacol. 1994. PMID: 8281629 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,042 results

Search Page

Filters